Helsinn to Launch Sales Organization in the United States

          Helsinn to Launch Sales Organization in the United States

  PR Newswire

  LUGANO, Switzerland, October 1, 2013

LUGANO, Switzerland, October 1, 2013 /PRNewswire/ --

TheSwiss Helsinn Group announced today the formation of a sales organization
in the US subsidiary, Helsinn Therapeutics (US) Inc. A commercial organization
of 20 people has been engaged throughout the United States. The new oncology
sales representatives will be working via a co-detailing agreement for Aloxi®
(palonosetron HCl injection), licensed by the Helsinn Group to Eisai, Inc. 

The establishment of this commercial organization in the United States
represents the next step in strengthening Helsinn's international presence.
"We are excited about entering the largest market in the world with a sales
organization. This new phase of Helsinn's growth into a fully integrated
oncology company builds on our existing and successful global business to
business capabilities. We are grateful to Eisai for their support in this new
opportunity. We remain strongly committed to developing and delivering
products that support cancer patients," commented Riccardo Braglia, Helsinn
Group's Chief Executive Officer.

About FDA-Approved Aloxi® (palonosetron HCl Injection)

Aloxi® (palonosetron HCl) injection 0.25 mg is the first and only IV 5-HT [3]
receptor antagonist to be indicated for the prevention of acute and delayed
nausea and vomiting associated with initial and repeat courses of moderately
emetogenic chemotherapy, and for the prevention of acute nausea and vomiting
associated with initial and repeat courses of highly emetogenic chemotherapy.

Important Safety Information

Aloxi® is contraindicated in patients known to have hypersensitivity to the
drug or any of its components. Hypersensitivity reactions, including
anaphylaxis, have been reported with or without known hypersensitivity to
other 5-HT [3] receptor antagonists. The most commonly reported adverse
reactions in Aloxi® chemotherapy-induced nausea and vomiting trials include
headache (9%) and constipation (5%). Please see the Aloxi® package insert,
available at http://www.aloxi.com , for important additional details.

About Chemotherapy-induced nausea and vomiting (CINV)

Chemotherapy-induced nausea and vomiting is among the most dreaded side
effects following therapy in patients with cancer. Despite prophylaxis, on the
day of chemotherapy, up to 30-45 percent of patients experience nausea or
vomiting or require rescue therapy following administration of certain types
of emetogenic chemotherapy. The 5-HT [3] receptor plays a pivotal role in the
process of emesis, and agents that antagonize these receptor subtypes are the
basis for control of this effect.

Following the development of the older5-HT [3] receptor antagonists, such as
ondansetron and granisetron, in the late '80s and early '90s, in recent years
new compounds have been made available for preventing CINV, including
palonosetron.

About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano,
Switzerland, and operating subsidiaries in Ireland, the United States and a
representative office in China. Helsinn's business model is focused on the
licensing of pharmaceuticals, medical devices and nutritional supplement
products in therapeutic niche areas. Helsinn is an important player in cancer
supportive care. Helsinn Group in-licenses early-to-late stage new chemical
entities, completes their development through the performance of pre-clinical
/clinical studies and Chemistry, Manufacturing, and Control (CMC) development,
and files and attains their market approvals worldwide. Helsinn's products are
out-licensed to its network of local marketing and commercial partners,
selected for their deep in-market knowledge and know-how whom Helsinn assists
and supports by providing a full range of product and scientific management
services, including commercial, regulatory, financial, legal, and medical
marketing advice. The active pharmaceutical ingredients and the finished
products are manufactured according to the highest quality, safety, and
environmental standards at Helsinn's GMP facilities in Switzerland and Ireland
and supplied worldwide to its customers.

Further information on Helsinn Group is available at http://www.helsinn.com .

Contact: Helsinn Group

Paola Bonvicini Head of Communication & Press Office PH +41-91-985-21-21
info-hhc@helsinn.com
 
Press spacebar to pause and continue. Press esc to stop.